ClinicalTrials.gg
RecruitingNCT05518786PreMed4PICSUpdated Oct 5, 2023

Precision Medicine for Post-Intensive Care Syndrome (PreMed4PICS)

An observational study in Postintensive Care Syndrome, sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-05.

Sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started May 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

Critically ill patients show an acute phase characterized by systemic spread of the inflammatory response, irrespectively of the cause of intensive care unit (ICU) admission, and late sequelae, including ICU acquired muscle weakness (ICUAW) and neurocognitive impairment. Mechanisms driving these late sequelae are unknown and there are no effective therapies to date. PreMed4PICS hypothesis is that skeletal muscle pathogenetic phenotypes and long-term sequelae in survivors to critical illness can be predicted at ICU admission in peripheral blood samples by transcriptomic profiling of the acute systemic response. Our main objective is to identify pathogenesis-dependent predictive signatures of muscle injury and clinical outcomes such as ICUAW or cognitive impairment. A multicentric prospective observational study will be conducted including adult patients admitted to the ICU and followed up until 12 months after ICU discharge. This will allow for clinical subphenotyping, sample acquisition and histopathological studies. To identify subphenotype-specific molecular pathways involved in skeletal muscle recovery, single-nuclei RNAseq will be performed. Massive sequencing of whole blood RNA and circulating microRNA at ICU admission will be performed to identify transcriptomic signatures that result in quantitative scores predictive of the outcomes of interest. All the findings will be confirmed in two validation cohorts. Collectively, this project aims to characterize the molecular mechanisms leading to ICUAW development and recovery, identifying therapeutic targets. The potential of a quantitative approach to the acute inflammatory response to predict long-term sequelae in survivors of critical illness will be validated.

Read the detailed description

The main objective of this project is to demonstrate that transcriptomic profiling of the acute systemic inflammatory response in patients admitted to the ICU predicts the main molecular pathways activated in the skeletal muscle at the onset of critical illness and during recovery, and the long term post-ICU sequelae. To achieve this objective the following specific aims have been established and organized into four work packages (WP) with specific objectives:

WP1: Clinical subphenotying and sampling in a large cohort of critically ill patients.

WP1.1. To characterize clinical features of the acute response to critical illness in two independents cohorts.

WP1.2. To evaluate long-term post-ICU sequelae after ICU discharge. WP1.3. To create a biobanked collection of samples from critically-ill patients.

WP2: Pathogenetic subphenotyping of skeletal muscle injury and recovery in critically ill patients.

WP2.1. To perform sn-RNAseq in muscle samples obtained at ICU admission and during the recovery phase from patients with and without persistent postICU muscle weakness.

WP2.2. To identify local pathogenetic subphenotypes according to the mechanisms involved in ICUAW development and recovery.

WP3: Transcriptomic profiling of peripheral whole blood during the acute response to critical illness.

WP3.1. To massively sequence gene expression and c-miRNA in peripheral blood obtained at ICU admission (discovery cohort).

WP3.2. To identify transcriptomic signatures in peripheral blood predictive of pathogenetic muscular phenotypes and long-term post-ICU sequelae.

WP3.3. To characterize the acute inflammatory profiles in response to critical illness according to the transcriptomic signatures.

02

Conditions studied

  • Postintensive Care Syndrome
03

In context

postintensive care syndrome

106 studies on the registry are indexed under postintensive care syndrome; 49 are open to participants now.

This study's planned enrollment of 200 is above the median of 135 across 56 observational studies indexed under postintensive care syndrome.

Browse postintensive care syndrome studies →

Lead sponsor

Fundación para la Investigación Biosanitaria del Principado de Asturias is the lead sponsor of 13 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients admitted to the ICU of three different tertiary university hospitals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted to ICU

Exclusion criteria

Exclusion Criteria:

  • Neurocritical patients
  • Previous neurocognitive or muscular impairments
  • Known neoplasia
  • Terminal illness
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • HUCA

    Patients recruited at the University Central Hospital of Oviedo

    Other: Exposure of interest: critical illness

  • Taulí

    Patients recruited at Parc Taulí Foundation/Hospital (Sabadell)

    Other: Exposure of interest: critical illness

  • Paz

    Patients recruited at University Hospital of La Paz (Madrid)

    Other: Exposure of interest: critical illness

Interventions

  • OtherExposure of interest: critical illness

    Patients admitted to an intensive care unit (ICU) will be followed-up to evaluate post-ICU long-term sequelae

06

What researchers measure

Primary outcomes

  1. ICU-acquired weakness

    Presence or absence of muscle weakness after critical illness at 12 months after ICU discharge.

    Time frame: 1 year

  2. Neurocognitive impairment

    Presence or absence of neurocognitive impairment in survivors of critical illness at 12 months after ICU discharge

    Time frame: 1 year

Secondary outcomes

  1. All-cause mortality

    All-cause mortality

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitario Central de Asturias (HUCA)
    Oviedo, Principado De Asturias 33011, Spain
    Recruiting
    • Laura Amado-Rodríguez, MD, PhD · Contactlar@crit-lab.org · +34 985652433
    • Laura Amado-Rodríguez, MD, PhD · Principal investigator
    • Guillermo Muñiz Albaiceta, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Data Management Plan will be implemented and followed-up during the project respecting the legal data privacy requirements in accordance with the General Data Protection Regulation 2016/679/EU (GDPR). Ethical principles will be rigorously respected. Genomic data will be shared in agreement with the Genomics Declaration. PreMed4PICS investigators will strive to make the data generated "FAIR", Findable, Accessible, Interoperable, and Reusable: Clinical data will be collected in RedCap, under the current legislation for this sensitive information. All recordings will be anonimized, and a master file linking anonymized data with patient IDs will be kept inside the hospital network. The code used to analyze will be shared at the public repository GitHub. All the code will be programmed in R language (open source).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The data will become available after public release of results, for at least 3 years after sharing.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Dec 2023, 43 months after the start.

Of 38 observational studies under postintensive care syndrome, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 50. This study's planned 43 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2022
First posted
Aug 29, 2022
StartActual
May 1, 2020
Primary completionEst.
Dec 30, 2023
CompletionEst.
May 31, 2025
Last update
Oct 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05518786
Lead sponsor
Fundación para la Investigación Biosanitaria del Principado de Asturias
Responsible party
Sponsor
First posted
Aug 29, 2022
Start date
May 1, 2020
Primary completion
Dec 30, 2023 (estimated)
Completion
May 31, 2025 (estimated)
Last update
Oct 5, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion